Cognetivity Neurosciences is a medical technology company developing an AI platform for early detection of cognitive impairment, dementia and Alzheimer's
#CognICA Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service #NHS:
https://t.co/TeTwHbZEyP
@FrontPubHealth
Our Latest PeerReviewed Study Highlights Cost-Efficiency and Improved Clinical Outcomes From Using #CognICA, Showing Savings of Over £40 Million Per Year Compared With Traditional #CognitiveAssessment Tools in Primary and Secondary Care.
https://t.co/uXTALRy33b
#HealthEconomics
Today marks #WorldAlzheimersDay. We’re proud of our partner @Cognetivity who are making major advancements in the #dementia detection space.
Learn more about our partnership: https://t.co/PheuTU5JmU
📣 Exciting Partnership Announcement on World Alzheimer's Day!
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology https://t.co/xDQN6PxTB5
#WorldAlzheimersDay#Cognetivity#NoFearCounselling
Thrilled to announce that we've won the prestigious #CogX2023 Award for Best AI Product in Health! A big shoutout to our incredible team at @Cognetivity. The future of #Alzheimers care is here and now. Let's connect and make an impact together! 🌟🧠🏆 #HealthTech#AI#Innovation
Excited to share our latest Publication! We explored how the Integrated Cognitive Assessment (ICA) can improve primary care referrals to memory services. 🧠
*ICA had Sensitivity of 93% for dementia
*Reduced unnecessary GP referrals by ~72%
https://t.co/zLneZxt2Gb
@Cognetivity
This is a great opportunity to enhance the benefits of early intervention and personalized care, ultimately promoting brain health, well-being, and improved quality of life. #CognetivityNeurosciences#CognICA#Alzheimers#Lecanemab
https://t.co/ktYUM65HNz
Following the approval of Leqembi, a breakthrough drug to treat Alzheimer's, our AI technology is positioned to provide crucial real-world evidence for the drug's effectiveness. As a result, our technology is well-positioned to provide the necessary basis for reimbursement by CMS